Heterologous vaccine therapy associated with half course of Miltefosine promote activation of the proinflammatory response with control of splenic parasitism in a hamster model of visceral leishmaniasis.

Simple item page
dc.contributor.authorCarvalho, Lívia Mendes
dc.contributor.authorFerreira, Francielle Carvalho
dc.contributor.authorGusmão, Miriã Rodrigues
dc.contributor.authorCosta, Ana Flávia Pereira
dc.contributor.authorBrito, Rory Cristiane Fortes de
dc.contributor.authorSoares, Rodrigo Dian de Oliveira Aguiar
dc.contributor.authorReis, Alexandre Barbosa
dc.contributor.authorCardoso, Jamille Mirelle de Oliveira
dc.contributor.authorCarneiro, Cláudia Martins
dc.contributor.authorRoatt, Bruno Mendes
dc.date.accessioned2023-01-26T19:14:11Z
dc.date.available2023-01-26T19:14:11Z
dc.date.issued2021pt_BR
dc.description.abstractVisceral leishmaniasis (VL) is a serious and neglected disease present worldwide. Chemotherapy using pentavalent antimony (SbV) is the most practical and inexpensive strategy available for the VL treatment today, however, it has high toxicity. Alternatively, other drugs are used as viable leishmanicidal therapeutic options. Miltefosine is the only anti-leishmanial agent administered orally, however, it has been reducing its effectiveness. In this sense, there is no ideal therapy for VL since the drugs currently used trigger severe side effects causing discontinuation of treatment, which carries an imminent risk for the emergence of parasite resistance. With that, other therapeutic strategies are gaining prominence. Among them, immunotherapy and/or immunochemotherapy, which the activation/modulation of the immune system can redirect the host’s immune response to an effective therapeutic result. Therefore, this work was designed to assess an immunochemotherapy protocol composed of half course of Miltefosine associated with LBSap vaccine (Milt+LBSap) using the hamster Mesocricetus auratus as an experimental model for VL treatment. When evaluating the main hematobiochemical, immunological and therapeutic efficacy parameters, it was demonstrated that the treatment with Milt+LBSap showed restoration of hematobiochemical condition and reduced serum levels of IgG-anti-Leishmania compared to animals infected non treated (INT). Beyond that, an increase in the number of CD4+ lymphocytes producers of IFN-γ in relation to INT or to animals treated with miltefosine during 28 days, and TNF-α increased compared to INT were observed. Also, it was found a reduction of IL-10-production in relation to INT, or animals that received LBSap vaccine only, or miltefosine, following by a reduction in the splenic parasitic burden. These results demonstrate that the immunochemotherapy protocol used can stimulate the immune response, inducing an expressive cellular response sufficient to control spleen parasitism, standing out as a promising proposal for the VL treatment.pt_BR
dc.identifier.citationCARVALHO, L. M. et al. Heterologous vaccine therapy associated with half course of Miltefosine promote activation of the proinflammatory response with control of splenic parasitism in a hamster model of visceral leishmaniasis. Current Research in Immunology, v. 2, p. 194-201, 2021. Disponível em: <https://www.sciencedirect.com/science/article/pii/S2590255521000202>. Acesso em: 11 out. 2022.pt_BR
dc.identifier.doihttps://doi.org/10.1016/j.crimmu.2021.10.003pt_BR
dc.identifier.issn2590-2555
dc.identifier.urihttp://www.repositorio.ufop.br/jspui/handle/123456789/16056
dc.language.isoen_USpt_BR
dc.rightsabertopt_BR
dc.rights.licenseThis is an open access article distributed under the terms of the Creative Commons license. Fonte: o PDF do artigo.pt_BR
dc.subjectLeishmania infantumpt_BR
dc.subjectImmunochemotherapypt_BR
dc.titleHeterologous vaccine therapy associated with half course of Miltefosine promote activation of the proinflammatory response with control of splenic parasitism in a hamster model of visceral leishmaniasis.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ARTIGO_HeterologousVaccineTherapy.pdf
Size:
2.41 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
DEACL - Artigos publicados em periódicos